Abstract
Breast cancer is one of the most prevailing tumors worldwide. Among its types, ductal carcinoma in situ (DCIS) currently represents 20-25% of diagnosed cases. Treatment options are invasive and/or have limited action spectrum, mainly represented by surgery, followed by radiotherapy and/or oral tamoxifen. However, this treatment standard has been questioned especially when it comes to low …